Alzinova announces new positive safety review of its Phase 1b study in Alzheimer’s disease
Alzinova AB (publ) (“Alzinova” or “the Company”), announces today that a second external safety review has been carried out of the Company's clinical phase 1b study - with a positive assessment to continue the study as planned. Behind the review is an independent expert group, Data and Safety Monitoring Board ("DSMB"), which continuously reviews the study. Based on the patients included in the study, the DSMB recommends continuing the study as planned without adjustments. The Company has previously communicated DSMB’s first review in April 2022, which also gave the green light to continue the